JP5361895B2 - 組成物 - Google Patents

組成物 Download PDF

Info

Publication number
JP5361895B2
JP5361895B2 JP2010530555A JP2010530555A JP5361895B2 JP 5361895 B2 JP5361895 B2 JP 5361895B2 JP 2010530555 A JP2010530555 A JP 2010530555A JP 2010530555 A JP2010530555 A JP 2010530555A JP 5361895 B2 JP5361895 B2 JP 5361895B2
Authority
JP
Japan
Prior art keywords
mbp
peptide
hla
composition
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010530555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500776A (ja
JP2011500776A5 (enExample
Inventor
デイビッド ライス，
ヘザー ストリーター，
Original Assignee
アピトープ テクノロジー （ブリストル） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by アピトープ テクノロジー （ブリストル） リミテッド filed Critical アピトープ テクノロジー （ブリストル） リミテッド
Publication of JP2011500776A publication Critical patent/JP2011500776A/ja
Publication of JP2011500776A5 publication Critical patent/JP2011500776A5/ja
Application granted granted Critical
Publication of JP5361895B2 publication Critical patent/JP5361895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
JP2010530555A 2007-10-31 2008-10-30 組成物 Active JP5361895B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0721430.7 2007-10-31
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962.3 2008-01-18
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (3)

Publication Number Publication Date
JP2011500776A JP2011500776A (ja) 2011-01-06
JP2011500776A5 JP2011500776A5 (enExample) 2011-10-06
JP5361895B2 true JP5361895B2 (ja) 2013-12-04

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530555A Active JP5361895B2 (ja) 2007-10-31 2008-10-30 組成物

Country Status (23)

Country Link
US (3) US8623827B2 (enExample)
EP (1) EP2211892B1 (enExample)
JP (1) JP5361895B2 (enExample)
KR (1) KR101570383B1 (enExample)
CN (1) CN101848725B (enExample)
AT (1) ATE518546T1 (enExample)
AU (1) AU2008320657B2 (enExample)
BR (1) BRPI0818302B1 (enExample)
CA (1) CA2703170C (enExample)
CY (1) CY1112620T1 (enExample)
DK (1) DK2211892T3 (enExample)
EA (1) EA017999B1 (enExample)
EC (1) ECSP10010211A (enExample)
HR (1) HRP20110724T1 (enExample)
IL (1) IL204662A (enExample)
MX (1) MX2010004698A (enExample)
MY (1) MY158800A (enExample)
NZ (1) NZ583924A (enExample)
PL (1) PL2211892T3 (enExample)
PT (1) PT2211892E (enExample)
SI (1) SI2211892T1 (enExample)
WO (1) WO2009056833A2 (enExample)
ZA (1) ZA201001748B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062321A (ko) * 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
KR101570383B1 (ko) 2007-10-31 2015-11-19 아피토프 테크놀러지 (브리스톨) 리미티드 조성물
JP5709876B2 (ja) 2009-10-12 2015-04-30 ライフバイオ ラボラトリーズ エルエルシーＬＩＦＥＢｉｏ ＬＡＢＯＲＡＴＯＲＩＥＳ ＬＬＣ 多発性硬化症治療用組成物
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
WO2018127828A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv Therapeutic method using tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
IL307722A (en) 2021-04-16 2023-12-01 Cour Pharmaceuticals Dev Company Inc A method of monitoring the existence of immunological tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
KR20030062321A (ko) * 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
KR101570383B1 (ko) 2007-10-31 2015-11-19 아피토프 테크놀러지 (브리스톨) 리미티드 조성물

Also Published As

Publication number Publication date
CA2703170C (en) 2016-10-11
BRPI0818302A2 (enExample) 2018-08-21
SI2211892T1 (sl) 2011-12-30
CN101848725B (zh) 2013-05-22
ZA201001748B (en) 2011-06-29
CN101848725A (zh) 2010-09-29
IL204662A (en) 2013-07-31
NZ583924A (en) 2012-06-29
MX2010004698A (es) 2010-05-13
MY158800A (en) 2016-11-15
WO2009056833A2 (en) 2009-05-07
BRPI0818302B1 (pt) 2022-04-12
DK2211892T3 (da) 2011-10-31
JP2011500776A (ja) 2011-01-06
EP2211892A2 (en) 2010-08-04
CA2703170A1 (en) 2009-05-07
WO2009056833A3 (en) 2009-11-26
KR101570383B1 (ko) 2015-11-19
HK1142803A1 (en) 2010-12-17
PL2211892T3 (pl) 2012-01-31
US20100286054A1 (en) 2010-11-11
EA017999B1 (ru) 2013-04-30
ECSP10010211A (es) 2010-08-31
US20160263188A1 (en) 2016-09-15
PT2211892E (pt) 2011-10-18
ATE518546T1 (de) 2011-08-15
US8623827B2 (en) 2014-01-07
US20140161832A1 (en) 2014-06-12
IL204662A0 (en) 2010-11-30
US9381234B2 (en) 2016-07-05
AU2008320657A1 (en) 2009-05-07
KR20100036391A (ko) 2010-04-07
EP2211892B1 (en) 2011-08-03
US9775880B2 (en) 2017-10-03
CY1112620T1 (el) 2016-02-10
EA201070541A1 (ru) 2010-12-30
AU2008320657B2 (en) 2013-09-05
HRP20110724T1 (hr) 2011-12-31

Similar Documents

Publication Publication Date Title
US9775880B2 (en) Methods of using myelin basis protein peptide compositions
US8961986B2 (en) Peptide composition
AU2025201115A1 (en) Method
JP6347065B2 (ja) ペプチド
JP2024520952A (ja) 免疫原性ペプチドを使用した改善された処置方法
AU2018206356B2 (en) Therapeutic method using tolerogenic peptides
ES2370957T3 (es) Composiciones que comprenden péptidos de la proteína básica de la mielina y sus utilizaciones médicas.
Kela-Madar et al. Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, β-Synuclein
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof
CN115298195B (zh) 一种包含s-阻遏蛋白肽的组合物
HK40016470A (en) Therapeutic method using dose escalation protocol for tolerogenic peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130903

R150 Certificate of patent or registration of utility model

Ref document number: 5361895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250